All Stories

  1. Beyond Prescriptions: Addressing Stagnation in Benzodiazepine Reduction in Acute Care Geriatric Wards in Japan
  2. Tongue Pressure: A Critical Bridge Between Oral Frailty and Systemic Longevity in Older Adults
  3. Integrating a Biopsychosocial and Neuroscientific Perspective Into Satoyama‐Based Frailty Research
  4. Noise Pareidolia Test for Delirium Prediction: Considering the Role of Dopaminergic Basal Ganglia Circuitry
  5. Attention to Elderspeak: A Call for Dignity-Affirming Communication in Advanced Nursing Care
  6. Effective Treatment With Olanzapine for Burning Mouth Syndrome With Denture Intolerance in an Older Patient: A Case Report
  7. Neuroscience‐Based Nomenclature: Bridging the Knowledge Gap for Safer Medication Management in Older Adult Care
  8. The evolving serotonin syndrome spectrum: from acute syndrome to smoldering presentations and personalized risk management
  9. Age, Sex, and Neuroinflammation: A Unified Mechanism for Burning Mouth Syndrome Driven by Small Fiber Neuropathy and Central Sensitization
  10. A Pharmacological and Critical Review of Caffeine and Alpha‐Lipoic Acid for Burning Mouth Syndrome
  11. Improving Communication With Older Adults Using a Self‐Reflection Questionnaire for Elderspeak: A Preliminary Proposal
  12. Managing Constipation in Older Adults on Atypical Antipsychotics: A Defecation Reflex and Gut Microbiota Approach
  13. The Oral–Brain Axis: A Novel Perspective on Bruxism and Orofacial Pain
  14. Bridging the Mind–Mouth Divide: Neuroscience's Essential Role in Dental Psychosomatic Education
  15. N-methyl-D-aspartate receptor as a therapeutic target for burning mouth syndrome
  16. Beyond Tooth Count: The Interplay of Oral Health, Frailty and Falls
  17. Burning Mouth Syndrome: A Neurological Reappraisal Through Idiopathic Intracranial Hypertension and Glymphatic Dysfunction
  18. Rethinking Burning Mouth Syndrome: A Nociplastic Pain Disorder Shaped by Sexual Dimorphism
  19. Real-World Prescribing Patterns and Treatment Continuation of Amitriptyline Monotherapy and Aripiprazole Augmentation for Medically Unexplained Oral Symptoms/Syndromes in Japan
  20. Commentary on “Examining the combined effects of social isolation and oral dysfunction on cognitive decline in community‐dwelling older Japanese adults”: Proposing a vicious cycle and holistic interventions
  21. Role of Brain Networks in Burning Mouth Syndrome: A Narrative Review
  22. Potential Target Receptors for the Pharmacotherapy of Burning Mouth Syndrome
  23. Memantine-Associated Decrease in Renal Function and Hyperuricemia
  24. Estrogen-Mediated Neural Mechanisms of Sex Differences in Burning Mouth Syndrome
  25. Life-threatening Neuroleptic Malignant Syndrome and Its Mechanism
  26. Pathogenesis of Orofacial Pain Based on Brain Circuits
  27. Molecular Mechanisms of Pain Regulation by Sex Hormones in Individuals With Burning Mouth Syndrome
  28. Challenges of Constipation in People Suffering from Schizophrenia: A Narrative Review
  29. Perioperative administration of esketamine during cesarean section is a double-edged sword
  30. Application of virtual reality technology improves the functionality of brain networks in individuals experiencing pain
  31. Investigating the Influence of Birth Month on the Incidence of Burning Mouth Syndrome
  32. Merits and demerits of administering esketamine in preventing postpartum depression following cesarean section
  33. Low‐dose amitriptyline: A potential therapeutic option for chronic pain in older people
  34. Facial aesthetics is shaped not only by genetic predispositions but also by the cultural norms and values
  35. The Role of the Gut Microbiota in Individuals with Irritable Bowel Syndrome: A Scoping Review
  36. Mechanisms of Drug-Associated Burning Mouth Syndrome
  37. Suicidality in individuals experiencing chronic orofacial pain
  38. The role of oral microbiota in the pathogenesis of burning mouth syndrome
  39. Chronic orofacial pain
  40. Responsiveness to amitriptyline in burning mouth syndrome
  41. Amitriptyline at low dose for burning mouth syndrome
  42. The effective perospirone augmentation with clonazepam for treatment‐resistant burning mouth syndrome: A case report
  43. Goal Attainment Scaling in Patients With Burning Mouth Syndrome: A Real-World Clinical Study Protocol
  44. QTc Shortening on Electrocardiogram With Amitriptyline May Indicate No Effect on Pain Relief in Burning Mouth Syndrome
  45. Guanfacine Used With Antipsychotics May Cause Bradycardia to Become Apparent After Discontinuation of Antipsychotics
  46. Spontaneous Pneumomediastinum in a Middle-Aged Female Patient With Schizophrenia: A Case Report
  47. Leukopenia associated with lamotrigine initiation after COVID-19 vaccine booster: A case report and literature review
  48. Effect of magnesium oxide with probiotics on bowel movements in elderly orthopedic patients with chronic constipation: a retrospective chart review
  49. Clinical Features and Variations of Pain Expressions in 834 Burning Mouth Syndrome Patients With or Without Psychiatric Comorbidities
  50. Burning mouth syndrome needs to consider the gut-brain axis from three types of pain: nociceptive, neuropathic, and nociplastic pain
  51. Poststroke Mania During the COVID-19 Pandemic
  52. Uric acid levels with tolvaptan treatment for syndrome of inappropriate antidiuretic hormone secretion
  53. Beware of attention‐deficit/hyperactivity disorder (ADHD) in older adults
  54. Dental conditions in patients with medically unexplained oral symptoms
  55. Sepsis associated with sodium glucose co‐transporter 2 inhibitor in an elderly patient with chronic kidney disease
  56. Comment on: The assessment of the long-term prognosis of burning mouth syndrome following treatment necessitates a reappraisal
  57. Letter to the Editor: Venous Neurovascular Compression and Chronic Orofacial Pain
  58. Antiviral Therapy for COVID-19 May Not Reduce Stroke Complications
  59. Preventing dehydration can help ensure safe use of psychotropic medications in the elderly
  60. Somatization and Medicalization in Patients with Unexplained Orofacial Pain
  61. Case series of drug-induced open bite: Extrapyramidal symptoms related to psychotropic medications
  62. Serotonin Paradox in Burning Mouth Syndrome
  63. Mild Decrease in Blood Glucose Levels May Predict Efficacy of Antipsychotic Lurasidone
  64. Impact of beta blockers on resting respiratory rate in older adults: A cross-sectional study
  65. Omicron variant infections and multiple strokes in older adults
  66. Beware of bihemispheric stroke after Omicron variant infection in the elderly
  67. Clozapine-Induced Fever and Plasma Cytokine Changes in a Patient With Schizophrenia
  68. Two-hit theory by estrogen in burning mouth syndrome
  69. Case report: Open bite as an extrapyramidal side effect with aripiprazole, a dopamine partial agonist
  70. Duloxetine-induced Hyponatremia Can Occur in Not Only Syndrome of Inappropriate Secretion of Antidiuretic Hormone but Also Cerebral Salt Wasting Syndrome
  71. Factors associated with the frequency of respiratory rate measurement by hospital nurses: a multicentre cross-sectional study
  72. How to facilitate respiratory rate measurement in the emergency room
  73. Beware of serotonin syndrome during the COVID-19 pandemic
  74. Beware of serotonin overload in pharmacotherapy for elderly patients with burning mouth syndrome
  75. The Effectiveness and Adverse Events of Amitriptyline and Aripiprazole in Very Elderly Patients With BMS
  76. Neuroleptic malignant syndrome associated with COVID-19 vaccination
  77. BRASH syndrome associated with angiotensin receptor blocker and SGLT2 inhibitor
  78. Metabolic Effects of Clozapine Administration Based on Sex Differences and the Relationships Between Dosage and Prolactin Levels: An Observational Study
  79. Foreign accent syndrome associated with left insula infarction after COVID-19 pneumonia
  80. Beware of Biphasic Anaphylaxis
  81. Biliary pseudolithiasis in an older patient treated with lascufloxacin
  82. Beware of traumatic anosmia in COVID-19 pandemic
  83. Long‐term preoperative use of zolpidem is associated with postoperative delirium in elderly patients undergoing hip surgery
  84. Prevalence and predictors of laxatives use in clozapine-related constipation: an observational study
  85. Careful use of clonazepam and alpha lipoid acid in burning mouth syndrome treatment
  86. Atypical diabetes mellitus caused by olanzapine
  87. Antipsychotic olanzapine-induced misfolding of proinsulin in the endoplasmic reticulum accounts for atypical development of diabetes
  88. Severe hypoglycemia in an elderly patient with Alzheimer's disease and with sepsis: The role of neurotransmitters on glucose regulation
  89. Cognitive decline due to the cerebral cavernous malformations
  90. Reply to the comments on “Aging is independently associated with an increasing normal respiratory rate among older adults without pulmonary disease and chronic heart failure”
  91. Eosinophilic pneumonia during treatment with clozapine: reports from a retrospective case series
  92. Contrasting characters of quick methods to measure respiratory rate in a clinical setting
  93. Duloxetine, a serotonin and norepinephrine reuptake inhibitor, may be a double-edged sword for patients with advanced Parkinson's disease
  94. The effect of probiotics on bowel movement and metabolic parameters in schizophrenia patients: a retrospective chart review
  95. Correspondence- ‘Role of Diffusion Weighted Imaging in Differentiating Benign from Pathological Vertebral Collapse using ADC Values’; Is It Possible to Discriminate Multiple Myeloma with Magnetic Resonance Imaging?
  96. Correspondence: Association of Serum Uric Acid Level with the Severity of Brain Injury and Patient’s Outcome in Severe Traumatic Brain Injury
  97. Letter Regarding the Article, ‘Hyponatremia in Patients Admitted with Stroke’; From the Viewpoint of Similarity to Hyponatremia Associated with Traumatic Brain Injury
  98. Therapeutic Dose of Amitriptyline for Older Patients with Burning Mouth Syndrome
  99. Acute psychosis secondary to atypical Bickerstaff brainstem encephalitis
  100. Aging is independently associated with an increasing normal respiratory rate among an older adult population in a clinical setting: A cross‐sectional study
  101. Primary prevention of Clostridioides difficile infection with combination probiotics
  102. Recurrence of eosinophilic pneumonia after clozapine treatment
  103. Duloxetine and Angiotensin II Receptor Blocker Combination Potentially Induce Severe Hyponatremia in an Elderly Woman
  104. A Comparison of Methods to Count Breathing Frequency
  105. Letter to the Editor on ‘PCR as a Diagnostic Tool for Extra-Pulmonary Tuberculosis’
  106. Is primary prevention of Clostridioides difficile infection possible with combination probiotics in elderly orthopedic patients?
  107. Correspondence: ‘Influenza as a Cause of SIADH Related Hyponatremia’
  108. Combination probiotics may prevent Clostridium difficile infection among elderly patients undergoing an orthopedic surgery
  109. Correspondence: Curious Case of Myocardial Infarction Caused by Lung Abscess- From the Viewpoint of Type 2 Myocardial Infarction by Chest Trauma
  110. Burning mouth syndrome: The challenge of an aging population
  111. Serum electrolyte levels may be associated with prefrontal hemodynamic responses in near infrared spectroscopy
  112. An increase in salivary flow with amitriptyline may indicate treatment resistance in burning mouth syndrome
  113. Serum prolactin levels are associated with prefrontal hemodynamic responses using near-infrared spectroscopy in male psychotic patients treated with antipsychotics
  114. Serum prolactin levels might become a useful marker for switching strategy to paliperidone palmitate in male schizophrenia patient
  115. 4G-β-D-galactosylsucrose as a prebiotics may improve underweight in inpatients with schizophrenia
  116. The QTc shortening with amitriptyline may indicate treatment resistance in chronic nonorganic orofacial pain
  117. Adrenaline reversal may be an unwarranted distraction during emergency cardiovascular care for patients treated with antipsychotics
  118. Responsibility of the doctor who prescribes serotonin and noradrenaline reuptake inhibitors for patients with chronic musculoskeletal pain
  119. Suvorexant as an orexin antagonist may regulate serum glucose levels in psychiatric patients with insomnia
  120. Carnitine may prevent health problems in hyperprolactinemia
  121. antipsychotic-induced hypoglycemia
  122. Iron Depletion Affects Dopamine Neurotransmissions
  123. Cerebral edema secondary to psychogenic polydipsia induced by tandospirone as add-on to olanzapine therapy
  124. Does olanzapine impair pancreatic beta-cell function directly?
  125. Olanzapine-induced severe hyperglycemia was completely reversed by the restoration of insulin secretion after switching to aripiprazole and initiating insulin therapy
  126. Erratum: Riwa Ozasa, Tetsuya Okada, Satomi Nadanaka, Takahiko Nagamine, Alisha Zyryanova, Heather Harding, David Ron, Kazutoshi Mori (2013) The Antipsychotic Olanzapine Induces Apoptosis in Insulin-secreting Pancreatic ^|^beta; Cells by Blocking PERK-m...
  127. The Antipsychotic Olanzapine Induces Apoptosis in Insulin-secreting Pancreatic β Cells by Blocking PERK-mediated Translational Attenuation
  128. Lithium Intoxication Associated with Angiotensin II Type 1 Receptor Blockers in Women
  129. Metabolic Effects of Sodium Valproate on Atypical Antipsychotics in Japanese Psychotic Patients
  130. Antipsychotic-induced hyperthermia in patients with behavioral and psychological symptoms of dementia
  131. Are psychotropic drugs involved in gallstone-induced acute abdomen in inpatients with schizophrenia?
  132. Carnitine Deficiency and Severe Hypoglycemia Associated with Valproic Acid
  133. Duloxetine-induced Hyponatremia in the Elderly
  134. Hypoprolactinemia and Extrapyramidal Symptoms in Male Schizophrenia or Psychotic Affective Disorder Patients Treated with Aripiprazole
  135. Metabolic Effects of Valproic Acid Augmentation in Male Schizophrenic Patients
  136. Are combination therapies with aripiprazole and other antipsychotics pharmacologically rational?
  137. What does antipsychotic-associated hypoprolactinemia mean in patients with chronic schizophrenia?
  138. Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study
  139. Severe Hyperglycemia Induced by Olanzapine was Improved with a Recovery of Insulin Secretion after Switching to Risperidone and Introducing Insulin Therapy
  140. Olanzapine-induced Elevation of Serum Triglyceride Levels in a Normal Weight Patient with Schizophrenia
  141. Direct metabolic effects of risperidone and olanzapine in Japanese schizophrenic patients
  142. Hypoglycemia associated with insulin hypersecretion following the addition of olanzapine to conventional antipsychotics
  143. Attitudes toward death in rural areas of Japan